Optic neuritis in different strains of mice by a recombinant hsv-1 expressing murine interleukin-2

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 7, 2009, Pages 3275-3282

  Zandian, Mandana ^a   Belisle, Raelene ^a   Mott, Kevin R ^a   Nusinowitz, Steven ^b   Hofman, Florence M ^c   Ghiasi, Homayon ^a  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; COLORING AGENT; INDOLE DERIVATIVE; LUXOL FAST BLUE MBS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMYELINATION; EVOKED VISUAL RESPONSE; FEMALE; HERPES SIMPLEX VIRUS 1; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OPTIC NEURITIS; PRIORITY JOURNAL; VIRUS RECOMBINANT; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; DEMYELINATING DISEASE; DISEASE MODEL; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VIRAL EYE INFECTION; VIROLOGY; VISUAL CORTEX;

ANIMALS; COLORING AGENTS; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; EVOKED POTENTIALS, VISUAL; EYE INFECTIONS, VIRAL; FEMALE; HERPESVIRUS 1, HUMAN; INDOLES; INTERLEUKIN-2; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OPTIC NEURITIS; VISUAL CORTEX;

EID: 67649995740     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3211     Document Type: Article

References (59)

1. Soderstrom M, Ya-Ping J, Hillert J, Link H. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology. 1998;50:708-714.
2. Sandberg-Wollheim M, Bynke H, Cronqvist S, Holtas S, Platz P, Ryder LP. A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol. 1990;27:386-393.
3. Rodriguez M, Siva A, Cross SA, O'Brien PC, Kurland LT. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology. 1995;45:244-250.
4. O'Riordan JI, Losseff NA, Phatouros C, et al. Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination. J Neurol Neurosurg Psychiatry. 1998;64:353-357.
5. Ghezzi A, Martinelli V, Torri V, et al. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol. 1999;246:770-775.
6. Lu CZ, Fredrikson S, Xiao BG, Link H. Interleukin-2 secreting cells in multiple sclerosis and controls. J Neurol Sci. 1993;120:99-106.
7. Gallo P, Piccinno M, Pagni S, Tavolato B. Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients. Ann Neurol. 1988;24:795-797.
8. Gallo P, Piccinno MG, Pagni S, et al. Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid. J Neurol Sci. 1989;92:9-15.
9. Trotter JL, Clifford DB, McInnis JE, et al. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol. 1989;25:172-178.
10. Greenberg SJ, Marcon L, Hurwitz BJ, Waldmann TA, Nelson DL. Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. N Engl J Med. 1988;319:1019-1020.
11. Hartung HP, Hughes RA, Taylor WA, Heininger K, Reiners K, Toyka KV. T cell activation in Guillain-Barre syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology. 1990; 40:215-218.
12. Bansil S, Troiano R, Cook SD, Rohowsky-Kochan C. Serum soluble interleukin-2 receptor levels in chronic progressive, stable and steroid-treated multiple sclerosis. Acta Neurol Scand. 1991;84: 282-285.
13. Traugott U. Multiple sclerosis: relevance of class I and class II MHC-expressing cells to lesion development. J Neuroimmunol. 1987;16:283-302.
14. Adachi K, Kumamoto T, Araki S. Interleukin-2 receptor levels indicating relapse in multiple sclerosis. Lancet. 1989;1:559-560.
15. Kittur SD, Kittur DS, Soncrant TT, et al. Soluble interleukin-2 receptors in cerebrospinal fluid from individuals with various neurological disorders. Ann Neurol. 1990;28:168-173.
16. Selmaj K, Nowak Z, Tchorzewski H. Multiple sclerosis: effect of myelin basic protein on interleukin 1, interleukin 2 production and interleukin 2 receptor expression in vitro. Clin Exp Immunol. 1988;72:428-433.
17. Selmaj K, Nowak Z, Tchorzewski H. Interleukin-1 and interleukin-2 production by peripheral blood mononuclear cells in multiple sclerosis patients. J Neurol Sci. 1988;85:67-76.
18. Yang J, Lindsberg PJ, Hukkanen V, Seljelid R, Gahmberg CG, Meri S. Differential expression of cytokines (IL-2, IFN-gamma, IL-10) and adhesion molecules (VCAM-1, LFA-1, CD44) between spleen and lymph nodes associates with remission in chronic relapsing experimental autoimmune encephalomyelitis. Scand J Immunol. 2002; 56:286-293.
19. Petitto JM, Streit WJ, Huang Z, Butfiloski E, Schiffenbauer J. Interleukin-2 gene deletion produces a robust reduction in susceptibility to experimental autoimmune encephalomyelitis in C57BL/6 mice. Neurosci Lett. 2000;285:66-70.
20. McCombe PA, Nickson I, Pender MP. Cytokine expression by inflammatory cells obtained from the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis induced by inoculation with myelin basic protein and adjuvants. J Neuroimmunol. 1998;88:30-38.
21. Nussenblatt RB, Thompson DJ, Li Z, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun. 2003; 21:283-293.
22. Ghiasi H, Osorio Y, Perng GC, Nesburn AB, Wechsler SL. Overexpression of interleukin-2 by a recombinant herpes simplex virus type 1 attenuates pathogenicity and enhances antiviral immunity. J Virol. 2002;76:9069-9078.
23. Perng GC, Dunkel EC, Geary PA, et al. The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J Virol. 1994;68:8045-8055.
24. Wechsler SL, Nesburn AB, Watson R, Slanina SM, Ghiasi H. Fine mapping of the latency-related gene of herpes simplex virus type 1: alternative splicing produces distinct latency-related RNAs containing open reading frames. J Virol. 1988;62:4051-4058.
25. Zwaagstra J, Ghiasi H, Nesburn AB, Wechsler SL. In vitro promoter activity associated with the latency-associated transcript gene of herpes simplex virus type 1. J Gen Virol. 1989;70:2163-2169.
26. Zwaagstra JC, Ghiasi H, Slanina SM, et al. Activity of herpes simplex virus type 1 latency-associated transcript (LAT) promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT transcript. J Virol. 1990;64:5019-5028.
27. Reddehase MJ, Mutter W, Koszinowski UH. In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection. J Exp Med. 1987;165:650-656.
28. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol. 1991;9:694-704.
29. Osorio Y, La Point SF, Nusinowitz S, Hofman FM, Ghiasi H. CD8+-dependent CNS demyelination following ocular infection of mice with a recombinant HSV-1 expressing murine IL-2. Exp Neurol. 2005;193:1-18.
30. Ghiasi H, Osorio Y, Perng GC, Nesburn AB, Wechsler SL. Recombinant herpes simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice. J Virol. 2001;75: 9029-9036.
31. Ghiasi H, Osorio Y, Hedvat Y, Perng GC, Nesburn AB, Wechsler SL. Infection of BALB/c mice with a herpes simplex virus type 1 recombinant virus expressing IFN-g driven by the LAT promoter. Virology. 2002;302:144-154.
32. Ghiasi H, Wechsler SL, Kaiwar R, Nesburn AB, Hofman FM. Local expression of tumor necrosis factor alpha and interleukin-2 correlates with protection against corneal scarring after ocular challenge of vaccinated mice with herpes simplex virus type 1. J Virol. 1995;69:334-340.
33. Nusinowitz S, Ridder W 3rd, Heckenlively JR. Electrodiagnostic Techniques for Visual Function Testing in Mice. Amsterdam: Kluwer; 2002.
34. Tilden AB, Itoh K, Balch CM. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. J Immunol. 1987;138:1068-1073.
35. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985;161:1169-1188.
36. Kundig TM, Schorle H, Bachmann MF, Hengartner H, Zinkernagel RM, Horak I. Immune responses in interleukin-2-deficient mice. Science. 1993;262:1059-1061.
37. Duquette P, Pleines J, Girard M, Charest L, Senecal-Quevillon M, Masse C. The increased susceptibility of women to multiple sclerosis. Can J Neurol Sci. 1992;19:466-471.
38. Kim S, Voskuhl RR. Decreased IL-12 production underlies the decreased ability of male lymph node cells to induce experimental autoimmune encephalomyelitis. J Immunol. 1999;162:5561-5568.
39. Zhang X, Castelli FA, Zhu X, Wu M, Maillere B, BenMohamed L. Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. Clin Vaccine Immunol. 2008;15:1436-1449.
40. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol. 1992;10:153-187.
41. Maatta JA, Nygardas PT, Hinkkanen AE. Enhancement of experimental autoimmune encephalomyelitis severity by ultrasound emulsification of antigen/adjuvant in distinct strains of mice. Scand J Immunol. 2000;51:87-90.
42. Binder TA, Greiner DL, Grunnet M, Goldschneider I. Relative susceptibility of SJL/J and B10.S mice to experimental allergic encephalomyelitis (EAE) is determined by the ability of prethymic cells in bone marrow to develop into EAE effector T cells. J Neuroimmunol. 1993;42:23-32.
43. Chiang CS, Powell HC, Gold LH, Samimi A, Campbell IL. Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice. J Clin Invest. 1996;97:1512-1524.
44. Campbell IL, Abraham CR, Masliah E, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A. 1993;90:10061-10065.
45. Pagenstecher A, Lassmann S, Carson MJ, Kincaid CL, Stalder AK, Campbell IL. Astrocyte-targeted expression of IL-12 induces active cellular immune responses in the central nervous system and modulates experimental allergic encephalomyelitis. J Immunol. 2000;164:4481-4492.
46. LaFerla FM, Sugarman MC, Lane TE, Leissring MA. Regional hypomyelination and dysplasia in transgenic mice with astrocyte-directed expression of interferon-gamma. J Mol Neurosci. 2000;15: 45-59.
47. Campbell IL, Stalder AK, Akwa Y, Pagenstecher A, Asensio VC. Transgenic models to study the actions of cytokines in the central nervous system. Neuroimmunomodulation. 1998;5:126-135.
48. Akwa Y, Hassett DE, Eloranta ML, et al. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol. 1998;161:5016-5026.
49. Challoner PB, Smith KT, Parker JD, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A. 1995;92:7440-7444.
50. Friedman JE, Lyons MJ, Cu G, et al. The association of the human herpesvirus-6 and MS. Mult Scler. 1999;5:355-362.
51. Boman J, Roblin PM, Sundstrom P, Sandstrom M, Hammerschlag MR. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology. 2000;54:265.
52. Martin C, Enbom M, Soderstrom M, et al. Absence of seven human herpesviruses, including HHV-6, by polymerase chain reaction in CSF and blood from patients with multiple sclerosis and optic neuritis. Acta Neurol Scand. 1997;95:280-283.
53. Mirandola P, Stefan A, Brambilla E, Campadelli-Fiume G, Grimaldi LM. Absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients. Neurology. 1999;53:1367-1368.
54. Pavan-Langston D. Ocular viral infections. Med Clin North Am. 1983;67:973-990.
55. Corey L. The current trend in genital herpes: progress in prevention. Sex Transm Dis. 1994;21:S38-S44.
56. Koelle DM, Ghiasi H. Prospects for developing an effective vaccine against ocular herpes simplex virus infection. Cur Eye Res. 2005; 30:929-942.
57. Bureau JF, Drescher KM, Pease LR, et al. Chromosome 14 contains determinants that regulate susceptibility to Theiler's virus-induced demyelination in the mouse. Genetics. 1998;148: 1941-1949.
58. Cua DJ, Groux H, Hinton DR, Stohlman SA, Coffman RL. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J Exp Med. 1999;189:1005-1010.
59. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea. 2001;20:1-13.